Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

High Incidence of Primary Resistance to Imatinib in the Group of Ph-Negative BCR-ABL- positive CML Patients,

Grigory Tsaur, Olga Plekhanova, Alexander Popov, Tatyana Riger, Anna Ivanova, Yulia Gryaznova, Ekaterina Nokhrina, Bulat Bakirov, Irina Krylova, Sergey Meresiy, Marina Shumkova, Egor Shorikov, Leonid Saveliev, Larisa Fechina

Blood (2011) 118 (21): 3772.

https://doi.org/10.1182/blood.V118.21.3772.3772

Published: 2011

Journal Articles

Qualitative and Quantitative Concordance of Minimal Residual Disease Data Assessed by Multicolor Flow Cytometry and PCR of Fusion Gene Transcripts In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia

Alexander Popov, Grigory Tsaur, MD, PhD, Tatiana Verzhbitskaya, Tatyana Riger, Yulia Yakovleva, Anna Ivanova, Alexander Druy, Egor Shorikov, Leonid Saveliev, Larisa Fechina, MD

Blood (2010) 116 (21): 1720.

https://doi.org/10.1182/blood.V116.21.1720.1720

Published: 2010

Journal Articles

Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib.

Grigory Tsaur, MD, PhD, Anna Ivanova, Alexander Popov, Yulia Yakovleva, Tatyana Riger, Olga Plekhanova, Yulia Ivanets, Andrey Misyurin, Marina Suchkova, Egor Shorikov, Leonid Saveliev, Larisa Fechina, MD

Blood (2010) 116 (21): 3422.

https://doi.org/10.1182/blood.V116.21.3422.3422

Published: 2010

Journal Articles

Minimal Residual Disease Monitoring by Quantification of Fusion Gene Transcripts In Infant with MLL- rearranged Acute Lymphoblastic Leukemia Treated by MLL-Baby Protocol

Grigory Tsaur, MD, PhD, Alexander Popov, Tatyana Nasedkina, Olga Kalennik, Anatoly Kustanovich, Olga Aleinikova, Tatyana Riger, Yulia Yakovleva, Anna Ivanova, Egor Shorikov, Leonid Saveliev, Larisa Fechina, MD

Blood (2010) 116 (21): 2731.

https://doi.org/10.1182/blood.V116.21.2731.2731

Published: 2010

Journal Articles

WT1 Gene Expression Limited Application for MRD Monitoring in AML Patients Carrying MLL Rearrangements.

Grigory Tsaur, MD, PhD, Alexander Popov, MD, PhD, fellow, Alexander Druy, Anna Ivanova, Tatyana Riger, MD, Olga Plekhanova, Yulia Svechnikova, MD, Egor Shorikov, MD, PhD, Claus Meyer, Rolf Marschalek, Leonid Saveliev, MD, PhD, Larisa Fechina, MD, PhD

Blood (2009) 114 (22): 4700.

https://doi.org/10.1182/blood.V114.22.4700.4700

Published: 2009

Journal Articles

MRD Monitoring in AML Patients with MLL-MLLT4 by Quantification of Fusion Gene Transcripts and Genomic Chromosomal Breakpoint Sequences

Grigory Tsaur, MD, PhD, Anna Ivanova, Olga Plekhanova, Tatyana Riger, MD, Yulia Yakovleva, MD, Alexander Popov, PhD, Yulia Svechnikova, MD, Olga Makarova, MD, Egor Shorikov, MD, PhD, Leonid Saveliev, MD, PhD, Claus Meyer, PhD, Rolf Marschalek, Larisa Fechina, MD, PhD

Blood (2008) 112 (11): 4888.

https://doi.org/10.1182/blood.V112.11.4888.4888

Published: 2008

Journal Articles

Molecular Remission in MLL/AF4-Positive Infant Leukemia Treated with the All Trans-Retinoic Acid Based MLL-Baby Protocol.

Grigory Tsaur, MD, PhD, Elizaveta Semenikhina, Anna Ivanova, Tatiana Nasedkina, PhD, Alexander Popov, Egor Shorikov, MD, PhD, Leonid Saveliev, MD, PhD, Larisa Fechina, MD, PhD

Blood (2007) 110 (11): 4254.

https://doi.org/10.1182/blood.V110.11.4254.4254

Published: 2007

NARROW

High Incidence of Primary Resistance to Imatinib in the Group of Ph-Negative BCR-ABL- positive CML Patients,

Qualitative and Quantitative Concordance of Minimal Residual Disease Data Assessed by Multicolor Flow Cytometry and PCR of Fusion Gene Transcripts In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia

Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib.

Minimal Residual Disease Monitoring by Quantification of Fusion Gene Transcripts In Infant with MLL- rearranged Acute Lymphoblastic Leukemia Treated by MLL-Baby Protocol

WT1 Gene Expression Limited Application for MRD Monitoring in AML Patients Carrying MLL Rearrangements.

MRD Monitoring in AML Patients with MLL-MLLT4 by Quantification of Fusion Gene Transcripts and Genomic Chromosomal Breakpoint Sequences

Molecular Remission in MLL/AF4-Positive Infant Leukemia Treated with the All Trans-Retinoic Acid Based MLL-Baby Protocol.

Email alerts

ASH Publications

American Society of Hematology

High Incidence of Primary Resistance to Imatinib in the Group of Ph-Negative BCR-ABL- positive CML Patients,

Qualitative and Quantitative Concordance of Minimal Residual Disease Data Assessed by Multicolor Flow Cytometry and PCR of Fusion Gene Transcripts In Childhood B-Cell Precursor Acute Lymphoblastic Leukemia

Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib.

Minimal Residual Disease Monitoring by Quantification of Fusion Gene Transcripts In Infant with MLL- rearranged Acute Lymphoblastic Leukemia Treated by MLL-Baby Protocol

WT1 Gene Expression Limited Application for MRD Monitoring in AML Patients Carrying MLL Rearrangements.

MRD Monitoring in AML Patients with MLL-MLLT4 by Quantification of Fusion Gene Transcripts and Genomic Chromosomal Breakpoint Sequences

Molecular Remission in MLL/AF4-Positive Infant Leukemia Treated with the All Trans-Retinoic Acid Based MLL-Baby Protocol.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only